Peptide vaccination in recurrent ALL

The aim of the study is to re-diagnose patients with a high risk of recurring ALL, to prevent a recurrence using immunological methods. For this, the participant receives an individual vaccine against components of their own leukemia cells. This vaccine stimulates the body's defense (the T cells) to find and destroy the leukemia cells. The preparation of the vaccine takes about 3 months, so that the participation in the study must be approved much earlier than at the beginning of treatment.

Children and adolescents from 1 to 18 years of age with a relapse of acute lymphoblastic leukemia are treated.

The inclusion of patients in Heidelberg has been possible since 01.11.2016.

  • Pediatric patients with ALL (T, B, pro-B, preB or c-ALL) in >= CR2 or >= CR1 after stem cell transplantation in morphologic remission (<5% bone marrow blasts or MRD <= 5x10-2) after treatment with chemotherapy and/or stem cell transplantation
  • Age 1-18
  • Presence of the written consent of the legal guardian

For more information, see the European Clinical Trials Register at EudraCT number: 2015-005281-29